Latest Financial Position News

Cynata Therapeutics has completed enrolment in major clinical trials for osteoarthritis and acute graft versus host disease, with pivotal results expected in the second quarter of 2026. The company also strengthened its patent portfolio and secured additional funding to extend its operational runway.

MEC Resources has bolstered its stake in Advent Energy with a $1.55 million loan while navigating a pivotal Federal Court hearing on the PEP 11 Joint Venture. Meanwhile, progress on Clean Hydrogen Technology signals potential growth avenues.

Bass Oil Limited reported a 7.9% rise in quarterly oil sales revenue and a 7.4% increase in production, alongside a pivotal gas sales agreement with Origin Energy for the Vanessa gas field, pending regulatory approval.

Indiana Resources has reported significant drilling results at its Minos Gold Project, including high-grade gold intersections up to 71 g/t, while also resolving a longstanding dispute with Tanzania. The company bolsters its exploration team and awaits assay results from nearby prospects.

Ionic Rare Earths has advanced its global rare earths strategy with a key US partnership, significant UK government funding, and progress in Brazil and Uganda, positioning itself as a critical player in sustainable magnet recycling and heavy rare earth supply.

Equatorial Resources has completed the final hearing in its high-stakes arbitration against the Republic of Congo and is pursuing clarity on permit cancellations in Guinea, all while maintaining a solid cash reserve.

Champion Iron Limited reported robust Q3 FY2026 results with record sales and ongoing progress on its DRPF project, while launching a significant acquisition offer for Rana Gruber.

Loyal Metals has secured and begun unlocking value from the Highway Reward Copper-Gold Mine, revealing substantial unmined mineralisation and advancing lithium projects in North America.

Broken Hill Mines has delivered a standout December quarter with record mining rates at Rasp Mine, strong exploration results, and a robust financial position, setting the stage for accelerated growth in 2026.

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.

Racura Oncology reported a transformative quarter with key scientific discoveries, expanded clinical programs, and a robust cash position of $20.94 million, setting the stage for pivotal cancer trials in 2026.

CurveBeam AI reported steady progress in Q2 FY26 with five new device purchase orders, a $4 million milestone payment pending receipt, and key regulatory submissions underway in the US and China.